Working… Menu

An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Patients With Primary Hyperoxaluria Type 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03350451
Recruitment Status : Active, not recruiting
First Posted : November 22, 2017
Last Update Posted : September 16, 2021
Information provided by (Responsible Party):
Alnylam Pharmaceuticals

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : June 2023